# US 2026/0297649 A1 · Modification of Pseudouridine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297649 A1
- Document ID: US20260297649A1
- Status: Published application
- Kind: A1
- Application number: 19/478,205
- Filed: 2024-04-26
- Published: 2026-10-01
- Earliest claimed: 2023-04-28
- Assignees: Ludwig Institute for Cancer Research
- Applicants: Ludwig Institute for Cancer Research Ltd
- Inventors: Haiqi Xu; Chun-Xiao Song
- Web page: https://patentgrep.com/patent/US20260297649A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/485: {involving kinase}
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/6869: Methods for sequencing
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A 2-bromoacrylamide-assisted cyclization sequencing (BACS) method permits quantitative profiling of pseudouridine (Ψ) at single-base resolution. Based on the bromoacrylamide cyclization chemistry, BACS induces Ψ-to-C mutation rather than truncation or deletion signatures during reverse transcription (RT), therefore providing higher resolution and enabling more accurate quantification of Ψ stoichiometry compared with CMC- and BS-based methods. Compared to known methods, BACS of the invention allows for the precise identification of Ψ positions, especially in densely modified Ψ regions and consecutive uridine sequences. Methods, compositions and kits are therefore possible for the detection of Ψ. In the context of RNA molecules, this allows for detection and sequencing of Ψ in such sequences.

## Claims

### Claim 1

A method of modifying pseudouridine comprising reacting the pseudouridine with a Michael Addition acceptor,
wherein the Michael Addition acceptor is a compound according to Formula (I):
wherein:
X is independently selected from halo, tosyl, mesyl, and triflyl;
R1 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, and C0-C4-alkylene-R1a, wherein R1a is independently selected from C3-C6 cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R1a is C3-C6 cycloalkyl or 4- to 6-membered heterocyclyl, R1a is optionally substituted with from 1 to 4 R1b, and where R1a is phenyl, R1a is optionally substituted with from 1 to 4 R1c;
R2 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, and C0-C4-alkylene-R2a, wherein R2a is independently selected from C3-C6 cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R2a is C3-C6 cycloalkyl or 4- to 6-membered heterocyclyl, R2a is optionally substituted with from 1 to 4 R2b, and where R2a is phenyl, R2a is optionally substituted with from 1 to 4 R2c;
R3 is independently selected from —C(O)OR3a, —C(O)R3a, —C(O)NR3bR3b, —CN, —NO2, —S(O)2OR3a, —S(O)2R3a, —S(O)2NR3bR3b, and 5- to 10-membered heteroaryl, wherein where R3 is 5- to 10-membered heteroaryl, R3 is optionally substituted with from 1 to 4 R3e;
R3a is independently selected from H, C1-C6-alkyl, C1-C6-haloalkyl, and C0-C6-alkylene-R3c; wherein where R3a is alkyl or haloalkyl, R3a is optionally substituted with a group selected from —N3, —C≡CH, Dibenzocyclooctynol (DIBO), Aza-dibenzocyclooctyne (DBCO), Bicyclononyne (BCN), trans-Cyclooctene (TCO), and Tetrazine;
R3b is independently selected from H, C1-C6-alkyl, C1-C6-haloalkyl, and C0-C6-alkylene-R3c; wherein where R3b is alkyl or haloalkyl, R3b is optionally substituted with a group selected from —N3, —C≡CH, Dibenzocyclooctynol (DIBO), Aza-dibenzocyclooctyne (DBCO), Bicyclononyne (BCN), trans-Cyclooctene (TCO), and Tetrazine;
or wherein two R3b groups, together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl group, optionally substituted with from 1 to 4 R3d;
R3c is independently selected from C3-C6 cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R3c is C3-C6 cycloalkyl or 4- to 6-membered heterocyclyl, R3c is optionally substituted with from 1 to 4 R3d, and where R3c is phenyl, R3c is optionally substituted with from 1 to 4 R3e;
R1b and R2b are each independently at each occurrence selected from ═O, ═S, halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, and C1-C4-haloalkyl;
R1c and R2c are each independently at each occurrence selected from halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, and C1-C4-haloalkyl;
R3d is independently at each occurrence selected from ═O, ═S, halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, —N3, —C≡CH, Dibenzocyclooctynol (DIBO), Aza-dibenzocyclooctyne (DBCO), Bicyclononyne (BCN), trans-Cyclooctene (TCO), and Tetrazine;
R3e is independently at each occurrence selected from halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, and C1-C4-haloalkyl, —N3, —C≡CH, Dibenzocyclooctynol (DIBO), Aza-dibenzocyclooctyne (DBCO), Bicyclononyne (BCN), trans-Cyclooctene (TCO), and Tetrazine;
R4 is independently at each occurrence selected from H and C1-C4-alkyl; or where two R4 groups are attached to the same nitrogen, those two R4 groups together with the nitrogen atom to which they are attached optionally form a 5- to 6-membered-heterocycloalkyl group optionally substituted with from 1 to 4 R5; and
R5 are each independently at each occurrence selected from ═O, ═S, halo, nitro, cyano, C1-C4-alkyl, and C1-C4-haloalkyl.

### Claim 2

A method of tagging or labelling pseudouridine in a sample, comprising reacting at least a portion of the sample with a Michael Addition acceptor, wherein the Michael Addition acceptor is a compound according to Formula (I):
wherein:
X is independently selected from halo, tosyl, mesyl and triflyl;
R1 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, and C0-C4-alkylene-R1a, wherein R1a is independently selected from C3-C6 cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R1a is C3-C6 cycloalkyl or 4- to 6-membered heterocyclyl, R1a is optionally substituted with from 1 to 4 R1b, and where R1a is phenyl, R1a is optionally substituted with from 1 to 4 R10;
R2 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, and C0-C4-alkylene-R2a, wherein R2a is independently selected from C3-C6 cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R2a is C3-C6 cycloalkyl or 4- to 6-membered heterocyclyl, R2a is optionally substituted with from 1 to 4 R2b, and where R2a is phenyl, R2a is optionally substituted with from 1 to 4 R2c;
R3 is independently selected from —C(O)OR3f, —C(O)R3f, —C(O)NR3eR3f, —S(O)2OR3f, —S(O)2R3f, —S(O)2NR3eR3f;
R3f is a linker covalently linked to an affinity tag or imaging probe;
R3g is independently selected from H, C1-C6-alkyl, and C1-C6-haloalkyl; R1b and R2b are each independently at each occurrence selected from ═O, ═S, halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, and C1-C4-haloalkyl;
R1c and R2c are each independently at each occurrence selected from halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, and C1-C4-haloalkyl;
R4 is independently at each occurrence selected from H and C1-C4-alkyl; or where two R4 groups are attached to the same nitrogen, those two R4 groups together with the nitrogen atom to which they are attached optionally form a 5- to 6-membered-heterocycloalkyl group optionally substituted with from 1 to 4 R5; and
R5 are each independently at each occurrence selected from ═O, ═S, halo, nitro, cyano, C1-C4-alkyl, and C1-C4-haloalkyl.

### Claim 3 (depends on 2)

A method as claimed in claim 2, wherein the affinity tag is selected from the group comprising biotin, FLAG tag, His-tag, HA tag, Strep-tag, Avi-tag, GST, c-myc-tag, V5-tag, E-tag, S-tag, SBP-tag, poly (Glu)-tag, calmodulin tag.

### Claim 4 (depends on 2, 3)

A method as claimed in claim 2 or claim 3, wherein the linker is a flexible linker, a cleavable linker; optionally a photocleavable linker.

### Claim 5 (depends on 4)

A method as claimed in claim 4, wherein the linker is selected from (a) a polyethylene glycol; (b) a peptide; (c) a nucleic acid; or (d) an oligosaccharide.

### Claim 6 (depends on 2)

A method as claimed in claim 2, wherein the imaging probe is selected from the group comprising fluorescent moieties, radionuclides and metal complexes.

### Claim 7 (depends on 6)

A method as claimed in claim 6, wherein the imaging probe is (a) a fluorophore selected from the group comprising a fluorescein, a rhodamine, BIODIPY, an Alexa fluor, a Cy dye or an ATTO dye; (b) a lanthanide complex; or (c) a radionuclide complex.

### Claim 8 (depends on 2, 3, 4, 5)

A method of isolating RNA comprising pseudouridine from a sample, comprising reacting the sample with a Michael Addition acceptor according to a method of any of claims 2 to 5, and then contacting the sample with a substrate comprising the binding partner to the affinity tag.

### Claim 9 (depends on 8)

A method as claimed in claim 8, wherein the affinity tag is biotin and the binding partner is avidin or streptavidin.

### Claim 10 (depends on 2, 6, 7)

A method of visualising pseudouridine in a sample comprising RNA, comprising reacting the sample with a Michael Addition acceptor according to a method of any of claims 2, 6 or 7, and subjecting the sample to a visualization procedure selected from optical observation, microscopical observation and image capture.

### Claim 11

A method of determining the presence and sequence location of pseudouridine comprised in a sample of RNA comprising:
(a) reacting at least a portion of the sample with a Michael Addition acceptor, wherein the Michael Addition acceptor is a compound according to Formula (I):
wherein:
X is independently selected from halo, tosyl, mesyl and triflyl;
R1 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, and C0-C4-alkylene-R1a, wherein R1a is independently selected from C3-C6 cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R1a is C3-C6 cycloalkyl or 4- to 6-membered heterocyclyl, R1a is optionally substituted with from 1 to 4 R1b, and where R1a is phenyl, R1a is optionally substituted with from 1 to 4 R1c;
R2 is independently selected from H, C1-C4-alkyl, C1-C4-haloalkyl, C0-C4-alkylene-R2a, wherein R2a is independently selected from C3-C6 cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R2a is C3-C6 cycloalkyl or 4- to 6-membered heterocyclyl, R2a is optionally substituted with from 1 to 4 R2b, and where R2a is phenyl, R2a is optionally substituted with from 1 to 4 R2c;
R3 is independently selected from —C(O)OR3a, —C(O)R3a, —C(O)NR3bR3b, —CN, —NO2, —S(O)2OR3a, —S(O)2R3a, —S(O)2NR3bR3b, and 5- to 10-membered heteroaryl, wherein where R3 is 5- to 10-membered heteroaryl, R3 is optionally substituted with from 1 to 4 R3e;
R3a is independently selected from H, C1-C6-alkyl, C1-C6-haloalkyl, and C0-C6-alkylene-R3c;
R3b is independently selected from H, C1-C6-alkyl, C1-C6-haloalkyl, and C0-C6-alkylene-R3c;
or wherein two R3b groups, together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl group, optionally substituted with from 1 to 4 R3d;
R3c is independently selected from C3—C cycloalkyl, phenyl, and 4- to 6-membered heterocyclyl; wherein where R3c is C3—C cycloalkyl or 4- to 6-membered heterocyclyl, R3c is optionally substituted with from 1 to 4 R3d, and where R3c is phenyl, R30 is optionally substituted with from 1 to 4 R3e;
R1b, R2b, and R3d are each independently at each occurrence selected from ═O, ═S, halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, and C1-C4-haloalkyl;
R1c, R2c, and R3e are each independently at each occurrence selected from halo, nitro, cyano, C(O)OR4, C(O)R4, C(O)NR4R4, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, and C1-C4-haloalkyl;
R4 is independently at each occurrence selected from H and C1-C4-alkyl; or where two R4 groups are attached to the same nitrogen, those two R4 groups together with the nitrogen atom to which they are attached optionally form a 5- to 6-membered-heterocycloalkyl group optionally substituted with from 1 to 4 R5; and
R5 are each independently at each occurrence selected from ═O, ═S, halo, nitro, cyano, C1-C4-alkyl, and C1-C4-haloalkyl;
(b) (i) sequencing the RNA; or (ii) reverse transcribing the RNA resulting from step (a) to provide cDNA and amplifying the cDNA;
(c) sequencing the DNA of step (b)(ii);
(d) comparing the DNA sequence of step (c) with a reference DNA sequence to identify the sequence positions of guanine (G) in the sequence which are adenine (A) in the reference sequence, the position of G in the DNA sequence being the positions of a pseudouridine in the corresponding RNA sequence.

### Claim 12 (depends on 11)

A method as claimed in claim 11, wherein the reference sequence is obtained from a separate portion of the RNA sample which is not subjected to Michael Addition reaction of step (a), but which is sequenced according to step (b)(i); or reverse transcribed according to step (b)(ii) and sequenced according to step (c).

### Claim 13 (depends on 11, 12)

A method as claimed in claim 11 or claim 12, wherein the amplification of cDNA employs an isothermal method of amplification; wherein the isothermal method of amplification is selected from polymerase chain reaction (PCR) strand-displacement amplification (SDA), rolling-circle amplification (RCA), whole-genome amplification (WGA), loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), and multiple displacement amplification (MDA); optionally wherein a one-step RT-PCT is used.

### Claim 14 (depends on 11, 12, 13)

A method as claimed in any of claims 11 to 13, wherein the reverse transcription of step (b) uses a reverse transcriptase enzyme; optionally selected from: Maxima H-, SuperScript II, SuperScript III, SuperScrupt IV, ProtoScript II, SMARTScribe, PrimeScript II, HiScript III, MMLV, AMV, TGIRT-III or recombinant HIV; preferably Maxima H-, SuperScript IV and TGIRT-III; more preferably Maxima H-.

### Claim 15

A method as claimed in any preceding claim, wherein X is selected from Br, Cl, and I.

### Claim 16

A method as claimed in any preceding claim, wherein at least one of R1 and R2 is H; optionally wherein both R1 and R2 are H.

### Claim 17

A method as claimed in any preceding claim, wherein R3 is independently selected from —C(O)OR3a, —C(O)R3a, —C(O)NR3bR3b, and —CN.

### Claim 18

A method as claimed in any preceding claim, wherein R3 is —C(O)NR3bR3b, optionally wherein R3 is —C(O)NH2.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method as claimed in any of claims 1 to 18, wherein the compound according to Formula (I) is selected from:

### Claim 20

A method as claimed in any preceding claim, wherein the Michael Addition reaction is performed at a pH in the range of from about 7.0 to about 9.5.

### Claim 21

A method as claimed in any preceding claim, wherein the Michael Addition acceptor is present at a concentration in the range from about 10 mM to about 2M; preferably in the range from about 100 mM to about 500 mM; more preferably about 250 mM.

### Claim 22

A method as claimed in any preceding claim, wherein the Michael Addition reaction is performed at a temperature in the range of from about 25° C. to about 95° C.; preferably from about 65° C. to about 95° C.; more preferably about 85° C.

### Claim 23

A method as claimed in any preceding claim, wherein the Michael Addition reaction is performed at a temperature of about 70° C. or greater for a time in the range of from about 5 minutes to about 2 hours; or at a temperature of about 70° C. or less for a time in the range of from about 2 hours to about 16 hours.

### Claim 24

A method as claimed in any preceding claim, wherein the RNA molecule is selected from one or more of mRNA, tRNA, rRNA, snRNA, miRNA, lncRNA or circRNA.

### Claim 25

A method as claimed in any preceding claim, wherein the RNA molecule is derived from a biological sample.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7)

A kit for modifying a pseudouridine comprising:
(a) a solution comprising a Michael Addition acceptor as set forth in any of claims 1 to 7, or 15 to 19;
(b) instructions for reacting a sample comprising pseudouridine with the solution.

### Claim 27 (depends on 2, 15, 16, 17, 18, 19)

A kit for tagging or labelling pseudouridine comprised in RNA, comprising:
(a) a solution comprising a Michael Addition acceptor as set forth in any of claims 2 or 15 to 19;
(b) instructions for reacting an RNA with the solution.

### Claim 28 (depends on 11, 15, 16, 17, 18, 19)

A kit for determining the presence of sequence location of pseudouridine comprised in RNA, comprising:
(a) a solution comprising a Michael Addition acceptor as set forth in any of claims 11 or 15 to 19;
(b) instructions for reacting an RNA with the solution.

### Claim 29 (depends on 26, 27, 28)

A kit as claimed in any of claims 26 to 28, further comprising one or more buffers.

### Claim 30 (depends on 28, 29)

A kit as claimed in claim 28 or claim 29, further comprising a reverse transcriptase enzyme; optionally a reverse transcriptase selected from: Maxima H-, SuperScript II, SuperScript III, SuperScrupt IV, ProtoScript II, SMARTScribe, PrimeScript II, HiScript III, MMLV, AMV, TGIRT-III, recombinant HIV, Marathon reverse transcriptase or Induro reverse transcriptase; preferably Maxima H-, SuperScript IV and TGIRT-III; more preferably Maxima H-.

### Claim 31 (depends on 28, 29, 30)

A kit as claimed in any of claims 28 to 30, further comprising a DNA polymerase; optionally a DNA polymerase selected from Taq DNA Polymerase, Bst DNA Polymerase or Bsu DNA Polymerase.
